Wednesday, Jan 21, 2026 · SEC filings

What the smart money revealed on Jan 21

Real insider buys19insiders · $1.47M
Real insider sales33insiders · $114M
Fund 13Fs filed—not loaded for this day
Activist 13Ds filed—not loaded for this day

421 insider filings came in. We hid 46 planned (10b5-1) sellers and 311 people whose filings were routine, like grants and tax withholding.

group

8 insiders at Cabaletta Bio (CABA) bought $296K of stock

Roles: CEO, President, General Counsel, Chief Commercial Officer, Chief Medical Officer, Director. Several insiders buying in the same few days is rare.

Cluster buy Form 4 Traded Jan 21
$296K
trending_up

Universal Safety Products (UUU) Director Milton Ault bought $570K

95,000 shares on the open market. Not a grant or an option exercise. Their past buys: 2 of 5 checked quarters beat the typical stock 6 months later.

Real buy Form 4 Past buys: 2 of 5 beat Traded Jan 16
$570K
trending_up

GameStop (GME) Director Alain Attal bought $260K

12,000 shares on the open market. Not a grant or an option exercise.

Real buy Form 4 Traded Jan 21
$260K
trending_up

Cosmos Health (COSM) CEO Grigorios Siokas bought $177K

353,321 shares on the open market. Not a grant or an option exercise. Their past buys: 4 of 7 checked quarters beat the typical stock 6 months later.

Real buy Form 4 Past buys: 4 of 7 beat Traded Jan 20
$177K
trending_up

Strategy (MSTR) Director Jane Dietze bought $99.5K

1,000 shares on the open market. Not a grant or an option exercise. Their past buys: 1 of 3 checked quarters beat the typical stock 6 months later.

Real buy Form 4 Past buys: 1 of 3 beat Traded Jan 20
$99.5K
trending_down

Goldman Sachs Group (GS) Director David Viniar sold $65.8M

Not marked as a planned 10b5-1 sale. Sold 41% of the shares they held directly. Still holds 100,000 shares.

Real sale Form 4 Sold 41% of stake Traded Jan 16
$65.8M
trending_down

BlackRock (BLK) CFO & Senior Managing Director Martin Small sold $31.7M

Not marked as a planned 10b5-1 sale. Sold 72% of the shares they held directly. Still holds 10,557 shares.

Real sale Form 4 Sold 72% of stake Traded Jan 16
$31.7M
trending_down

Delta Air Lines (DAL) EVP & Chief Cust Exper Officer Erik Snell sold $2.8M

Not marked as a planned 10b5-1 sale. Sold 53% of the shares they held directly. Still holds 35,625 shares.

Real sale Form 4 Sold 53% of stake Traded Jan 16
$2.8M
Show 7 more real buys
Show 30 more real sales
AGX Argan · Director William Leimkuhler · Traded Jan 16
$4.19M
PTGX Protagonist Therapeutics · President and CEO Patel Dinesh V Ph D · Traded Jan 20
$2.84M
AGX Argan · Director John Jeffrey · Traded Jan 20
$1.03M
PTGX Protagonist Therapeutics · Chief Medical Officer Arturo Molina · Traded Jan 20
$785K
PTGX Protagonist Therapeutics · CFO Asif Ali · Traded Jan 20
$708K
MIRM Mirum Pharmaceuticals · Chief Medical Officer Joanne Quan · Traded Jan 20
$624K
JBHT J.B. Hunt Transport Services · EVP and COO Nicholas Hobbs · Traded Jan 20
$614K
IRMD Iradimed · CEO Roger Susi · Traded Jan 20
$509K
DRI Darden Restaurants · President Elect John Wilkerson · Traded Jan 16
$481K
SRRK Scholar Rock Holding · Chief Scientific Officer Mo Qatanani · Traded Jan 16
$374K
SRRK Scholar Rock Holding · General Counsel Junlin Ho · Traded Jan 16
$357K
SRRK Scholar Rock Holding · Chro Caryn Parlavecchio · Traded Jan 16
$294K
OLMA Olema Pharmaceuticals · Director Cyrus Harmon · Traded Jan 20
$269K
SRRK Scholar Rock Holding · Chief Medical Officer Jing Marantz · Traded Jan 16
$258K
APLS Apellis Pharmaceuticals · CEO Cedric Francois · Traded Jan 20
$162K
TSQ Townsquare Media · COO Erik Hellum · Traded Jan 16–20
$77.5K
OM Outset Medical · Chair and CEO Leslie Trigg · Traded Jan 20–21
$71.1K
ABEO Abeona Therapeutics · Director Mark Alvino · Traded Jan 21
$70.6K
OFIX Orthofix Medical · CFO Julie Andrews · Traded Jan 16
$70.1K
APLS Apellis Pharmaceuticals · CFO Timothy Sullivan · Traded Jan 20
$57.2K
OM Outset Medical · General Counsel John Brottem · Traded Jan 20–21
$53.6K
APLS Apellis Pharmaceuticals · General Counsel David Watson · Traded Jan 20
$49K
APLS Apellis Pharmaceuticals · Chief Technical Officer Nur Nicholson · Traded Jan 20
$43.6K
APLS Apellis Pharmaceuticals · Chief Medical Officer Caroline Baumal · Traded Jan 20
$37.2K
OM Outset Medical · EVP Operations R&D & Service Marc Nash · Traded Jan 20–21
$32.4K
APLS Apellis Pharmaceuticals · Chief Business & Strat Officer Mark DeLong · Traded Jan 20
$26.4K
APLS Apellis Pharmaceuticals · Chief Scientific Officer Pascal Deschatelets · Traded Jan 20
$18K
APLS Apellis Pharmaceuticals · VP/Chief Accounting Officer James Chopas · Traded Jan 20
$14.4K
CBDS Dogecoin Cash · CEO David Tobias · Traded Jan 16
$8.61K
ESPR Esperion Therapeutics · General Counsel Benjamin Looker · Traded Jan 20
$4.86K

13F season

Holdings as of Dec 31, 2025 are due Feb 17

320 funds have filed so far. 81 filed for the quarter before.

Biggest real insider buys this week

Open-market buys by officers and directors, filed in the 7 days up to Jan 21.

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate. Daily closing prices come from post-no-preference/stocks on DoltHub, a community-run database shared under CC BY-SA 4.0; the prices we show stay under that license. They are each day's close, not live or official exchange prices.

This is data, not investment advice. About StockToast · Your watchlist